Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
EVAX Catalyst Timeline
Dated clinical, regulatory and corporate events for Evaxion A/S
Catalyst Timeline
Dated clinical, regulatory & corporate events for Evaxion A/S
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How EVAX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-06 | EVX-01 | Phase 2 data presentation | Phase 2 |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EVX-01 VaccinesCompletedNCT05309421 | Melanoma Stage IV | Phase 2 | COMPLETED | 17 | Apr 7, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every EVAX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in EVAX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 245.01 K | 74.70 K |
Ownership Trends
EVAX Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How EVAX ranks across every disease it competes in
EVAX News
Evaxion announce 2027 financial calendar
Evaxion A/S has released its financial calendar for 2027, detailing key dates for business updates and financial results. Significant dates include the annual general meeting on April 29 and quarterly updates throughout the year. The company emphasizes its commitment to developing novel immunotherapies using its AI-Immunology platform.
Read more →Evaxion files amendment to registration statement related to 2025 EIB debt settlement agreement
Evaxion A/S has filed an amendment to its registration statement regarding a debt settlement agreement with the European Investment Bank. This agreement, finalized in July 2025, converted €3.5 million of debt into equity through warrants. The amendment does not involve a capital raise, and Evaxion will not receive proceeds from any sales by the EIB.
Read more →New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01
Evaxion A/S announced new biomarker data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. The data shows strong immune responses and supports the predictive accuracy of the AI-Immunology platform. Notably, 89% of vaccine targets achieved tumor-specific immune responses, with sustained clinical responses observed over three years.
Read more →Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting
Evaxion A/S will present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the ASH Annual Meeting in December 2026. The data support EVX-04's potential, showing broad patient coverage and effective T-cell responses. This builds on previous findings that demonstrated strong immune responses and tumor growth inhibition in preclinical models.
Read more →Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
Evaxion A/S will present new biomarker data from its phase 2 trial of EVX-01 at the SITC 2026 Annual Meeting. The trial showed a 75% objective response rate in advanced melanoma patients, with four achieving complete responses. The data will be shared in both oral and poster sessions during the event in Phoenix, Arizona.
Read more →Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution
Evaxion A/S has been awarded the 2026 International Prix Galien Award for its AI-Immunology™ platform, recognized as the best digital health solution. This marks the first time a Danish company has received this prestigious award. The platform is designed to enhance immunotherapy development for cancer and other diseases.
Read more →Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
Evaxion announced promising three-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. The results showed 89% of vaccine neoantigens elicited strong T-cell responses, with no tumor progression in patients. This data will be presented at the ESMO Congress 2026, highlighting the durability of clinical responses.
Read more →Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
Evaxion A/S announced promising three-year follow-up data from its phase 2 trial of the personalized cancer vaccine EVX-01 for advanced melanoma. All patients maintained their clinical responses, with no tumor progression observed. The results, showcasing a 75% Objective Response Rate, will be presented at the ESMO Congress 2026, highlighting the vaccine's potential in treating hard-to-treat cancers.
Read more →Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
Evaxion A/S will present new immune data for its personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The data, derived from a phase 2 trial, highlights the vaccine's systemic immunomodulatory effects when combined with pembrolizumab in advanced melanoma patients. The findings will be shared through both oral and poster presentations.
Read more →Evaxion applies its AI-Immunology™ platform in autoimmune diseases
Evaxion A/S is applying its AI-Immunology™ platform to develop treatments for autoimmune diseases, addressing a significant unmet medical need. The company is testing two novel concepts: a tolerogenic vaccine and an autoantibody binder. Initial data will be presented at the upcoming Protein & Antibody Engineering Summit in Lisbon on November 18, 2026.
Read more →Evaxion announces business update and second quarter 2026 financial results
Evaxion A/S has provided a business update and financial results for Q2 2026, highlighting significant advancements in its R&D pipeline, including upcoming presentations of clinical data for its cancer vaccine candidates. The company has been recognized for its AI-Immunology platform, winning the 2026 Prix Galien UK Award. Despite a net loss of $3.7 million, Evaxion maintains a cash runway into the second half of 2027.
Read more →Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program
Evaxion A/S has announced the expansion of its R&D pipeline with EVX-05, an AI-designed vaccine targeting glioblastoma. This off-the-shelf therapeutic vaccine aims to address the significant unmet medical needs in treating this aggressive brain cancer. The company is collaborating with Duke University for initial clinical testing, while maintaining a robust cash runway into 2027 despite discontinuing the EVX-03 program.
Read more →Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026
Evaxion A/S will announce its business update and second quarter 2026 financial results on August 20, 2026. The company will host a conference call and webcast at 14:30 CET/08:30 EST to present the results and answer questions. Evaxion focuses on developing novel vaccines using its AI-Immunology platform, addressing significant medical needs.
Read more →Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
Evaxion A/S will present three-year clinical efficacy data for its personalized cancer vaccine EVX-01 at the ESMO Congress 2026. This data, stemming from a phase 2 trial, will provide insights into the vaccine's effects as a stand-alone treatment for advanced melanoma. Previous two-year results showed a 75% objective response rate and significant durability of responses.
Read more →Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1
Evaxion A/S presented promising preclinical data for its cytomegalovirus vaccine program EVX-V1 at the International Herpesvirus Workshop 2026. The data indicates that the vaccine could improve control of CMV infections through a multi-component approach that utilizes AI-discovered antigens. This advancement is crucial as CMV poses significant health risks, particularly to immunocompromised individuals and infants.
Read more →Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
Evaxion A/S will present new preclinical data for its cytomegalovirus vaccine candidate, EVX-V1, at the International Herpesvirus Workshop in Montreal. The data will aid in the final selection of antigens for the vaccine, which combines novel AI-discovered and optimized components. This innovative approach aims to enhance the vaccine's protective potential against CMV.
Read more →Evaxion receives Prix Galien UK Award for Best digital health solution
Evaxion A/S has been awarded the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology™ platform. This recognition highlights the platform's capabilities in developing novel vaccines for cancer and infectious diseases. The award was presented to CEO Helen Tayton-Martin at a ceremony in London, marking a significant achievement for the company.
Read more →Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
Evaxion A/S has announced promising preclinical data for its therapeutic vaccine EVX-04, targeting acute myeloid leukemia (AML). The vaccine is shown to be effectively expressed and secreted in human cells, driving specific immune responses that mediate targeted cell-killing. This data will be presented at the EHA 2026 Congress, highlighting its potential as a novel treatment option for AML patients.
Read more →Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
Evaxion A/S will present new preclinical data for EVX-04, a therapeutic vaccine for acute myeloid leukemia (AML), at the EHA 2026 Congress in Stockholm. The data will focus on the functional characterization of EVX-04, which targets specific tumor antigens. The company plans to submit a clinical trial application later in 2026.
Read more →Evaxion announces business update and first quarter 2026 financial results
Evaxion A/S reported a positive business update alongside its Q1 2026 financial results, highlighting significant advancements in its AI-Immunology™ platform. The company achieved an 86% vaccine target recognition rate for its personalized cancer vaccine, EVX-01, and successfully extended its phase 2 trial. Additionally, Evaxion is developing new polio vaccine concepts in collaboration with The Gates Foundation. Despite a net loss increase, the company maintains a cash runway into 2027.
Read more →